Compugen to Collaborate with Teva on Toxicity Biomarker Discovery | GenomeWeb
NEW YORK (GenomeWeb News) - Compugen today said it has signed a collaboration with Teva Pharmaceuticals to discovery biomarkers that could predict nephrotoxicity.
 
The agreement also may be expanded to include biomarker development for hepatoxicity and cardiotoxicity, Compugen said.
 
Under the agreement, Compugen will use its computational tools and nucleic acid testing technologies to analyze biological samples collected by Teva in a preclinical study.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.